[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507226":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":50,"collaborators":19,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":19,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"IRCCS Sacro Cuore Don Calabria di Negrar","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment arm","EXPERIMENTAL","Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy",[13],"Radiation: Daily Adaptive RadioTherapy",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"RADIATION","Daily Adaptive RadioTherapy",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Luca Nicosia","IRCCS Sacro Cuore Don Calabria - Dipartimento di Radioterapia Oncologica Avanzata","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Elvia Malo","CONTACT","+390456014854","ricerca.clinica@sacrocuore.it",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Negrar","Verona","37024","Italy","IT",{"type":40,"coordinates":41},"Point",[42,43],10.93899,45.52918,{"lat":43,"lon":42},[46],{"name":47,"role":28,"phone":48,"phoneExt":19,"email":49},"Luca Nicosia, Doctor","+39(0)456014800","luca.nicosia@sacrocuore.it",{"type":51,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100507226","daily-adaptive-radiotherapy-in-postoperative-hypofractionated-salvage-radiotherapy-for-prostate-cancer-patients-100507226",false,"NCT05884632","Daily Adaptive RadioTherapy in Postoperative HypofrActionated Salvage radiothERapy for Prostate Cancer Patients","DART-PHASER","Inclusion Criteria:\n\n* Age ≤ 80 years;\n* Prostate cancer diagnosis, pT2-3 pN0, any resection margin (R0 or R1);\n* Indication to local salvage treatment defined as: early salvage radiotherapy after primary prostate surgery (radical prostatectomy) with PSA \\\u003C0.2 ng\u002Fml or salvage radiotherapy after primary prostate surgery (radical prostatectomy) with PSA ≥0.2 ng\u002Fml;\n* No distant metastases (M0) diagnosed with PSMA-PET-CT;\n* Informed consent to trial's participation and personal data treatment.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old;\n* Adjuvant radiotherapy;\n* Previous radiation in the same anatomical site.","MALE","18 Years","80 Years",{"count":63,"type":64},184,"ESTIMATED","INTERVENTIONAL",[67],"NA","This is a monoinstitutional prospective pilot study, aiming to evaluate treatment-related toxicity of an hypofractionated postoperative salvage radiotherapy with daily-adaptive modality in patients affected by prostate cancer biochemical recurrence.\n\nPatients will be treated with postoperative hypofractionated salvage radiotherapy with a dose of 59 Gy in 20 fractions with daily-adaptive modality. Considering the consolidate role and clinical outcome of postoperative hypofractionated radiotherapy with elevate level of evidence (8-10), the study will not be controlled, but compared with literature data.",[70],"Prostate Cancer","2023-05-23",{"date":73,"type":74},"2023-06-01","ACTUAL",{"date":76,"type":74},"2023-04-03",{"date":78,"type":64},"2030-04-30",{"name":5,"class":6},1]